Results 31 to 40 of about 137,000 (307)

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran, Meier, Katharina, Solimani, Farzan   +2 more
core   +1 more source

JAK Inhibitors in Psoriatic Disease

Clinical, Cosmetic and Investigational Dermatology, 2023
Psoriasis is now considered to be the cutaneous phenotype of a systemic inflammatory condition, recognized under the term Psoriatic Disease (PsD). PsD has several extracutaneous manifestations, such as inflammatory articular and entheseal involvement, leading to psoriatic arthritis (PsA), and the less frequent intestinal and ocular manifestations with ...
Megna, Matteo, Potestio, Luca, Ruggiero, Angelo, Cacciapuoti, Sara, Maione, Francesco, Tasso, Marco, Caso, Francesco, Costa, Luisa   +7 more
openaire   +5 more sources

Methotrexate Is a JAK/STAT Pathway Inhibitor. [PDF]

PLoS ONE, 2015
The JAK/STAT pathway transduces signals from multiple cytokines and controls haematopoiesis, immunity and inflammation. In addition, pathological activation is seen in multiple malignancies including the myeloproliferative neoplasms (MPNs).
Sally Thomas, Katherine H Fisher, John A Snowden, Sarah J Danson, Stephen Brown, Martin P Zeidler   +5 more
doaj   +1 more source

Network pharmacology of JAK inhibitors [PDF]

Proceedings of the National Academy of Sciences, 2016
SignificanceJAK kinase inhibitors (JAKis) have advanced options for treatment of autoimmune diseases. Because JAKs are signaling hubs for several cytokine receptors, JAKis’ overall impact on the immune system and how they actually improve diseases like rheumatoid arthritis remain poorly understood.
Devapregasan, Moodley, Hideyuki, Yoshida, Sara, Mostafavi, Natasha, Asinovski, Adriana, Ortiz-Lopez, Peter, Symanowicz, Jean-Baptiste, Telliez, Martin, Hegen, James D, Clark, Diane, Mathis, Christophe, Benoist   +10 more
openaire   +2 more sources

Future therapeutic targets in rheumatoid arthritis? [PDF]

, 2017
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. Without adequate treatment, patients with RA will develop joint deformity and progressive functional impairment.
A Balanescu, A Bilancio, A Del Prete, A Maas, AB Avci, AB Satterthwaite, AD Cook, AG Semb, AJ Fleetwood, AJ Fleetwood, AJ Mohamed, AL Bell, AL Cornish, AM Condliffe, AR Pettit, AW Lieshout van, B Ludewig, BF Nashed, BJ Jenkins, BZ Li, C Baerwald, C Meune, C Rommel, C Schindler, C Voigtlander, CA Martin, CJ Heijnen, CM Hilkens, CV Brenol, D Heijde van der, DH Solomon, DJ Rawlings, DL Bellinger, DM Nance, DS Lim, DT Patton, E Banham-Hall, E Clayton, E Feist, E Hirsch, E Martin, E Thomas, EB Lee, EC Tsark, EK Evans, F Berenbaum, F Bussolino, F Ramadani, FA Koopman, FA Koopman, FM Foster, G Hansen, GM Bell, GR Burmester, GR Burmester, H Evrengul, H Wang, Iain B. McInnes, IC Eijk van, IJ Elenkov, IK Campbell, J Askling, J Jang, J Kremer, JA Avina-Zubieta, JA Hamilton, JC Barrientos, JE Park, JM Kremer, JM Waldburger, JS Rawlings, JS Smolen, K Imada, K Okkenhaug, K Okkenhaug, K Okkenhaug, K Pavelka, K Reif, K Shuai, K Thiele, K Yamaoka, KL Winthrop, KP MacDonald, KS Nair, L Conti, L Jansson, L Senolt, L Zhang, L Zou, LC Cantley, LG Schipper, LJ Courtright, LV Borovikova, M Camps, M Dougados, M Field, M Gilliet, M Pesu, M Rosas-Ballina, M Skoberne, M Skoberne, M Soubrier, M Westman, MA Maanen van, MA Maanen van, MA Maanen van, MB Torchinsky, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Lebre, MC Lebre, MG Roncarolo, MJ Peters, MS Ahmed, MS Thomas, N Krishnamoorthy, N Sato, NJ Gullick, P Geborek, P Norman, P Sujobert, PC Heinrich, PC Taylor, Q Yang, R Fleischmann, R Fleischmann, RA Maldonado, RF Vollenhoven van, RH Straub, RM Buijs, RM Steinman, RM Steinman, S Hayer, S Kleinau, S Mukhopadhyay, S Mukhopadhyay, S Somersan, S Tsukada, SA Provan, ST Jou, T Leizer, T Li, Tommy Tsang Cheung, TR Radstake, WJ Jonge de, WN Khan, Y Ren, Y Xu, YP Goekoop-Ruiterman, Z Li, Z Pan   +154 more
core   +1 more source

Suppressor of Cytokine Signaling-3 (SOCS-3) induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) expression in hepatic HepG2 cell line [PDF]

, 2015
The suppressor of cytokine signaling (SOCS) proteins are negative regulators of the JAK/STAT pathway activated by proinflammatory cytokines, including the tumor necrosis factor (TNF-\u3b1).
Corsini, Alberto, Cristofani, Riccardo, Ferri, Nicola, Liu, Jingwen, Macchi, Chiara, Magni, Paolo, Ricci, Chiara, Ruscica, Massimiliano   +7 more
core   +2 more sources

JAK inhibitors and COVID-19

Journal for ImmunoTherapy of Cancer, 2022
During SARS-CoV-2 infection, the innate immune response can be inhibited or delayed, and the subsequent persistent viral replication can induce emergency signals that may culminate in a cytokine storm contributing to the severe evolution of COVID-19. Cytokines are key regulators of the immune response and virus clearance, and, as such, are linked to ...
Gabriel Levy, Paola Guglielmelli, Peter Langmuir, Stefan N Constantinescu   +3 more
openaire   +6 more sources

CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition. [PDF]

, 2019
Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a genetically heterogeneous subtype of B-cell ALL characterized by chromosomal rearrangements and mutations that result in aberrant cytokine receptor and kinase signaling.
Delgado-Martin, Cristina, Hermiston, Michelle L, Maude, Shannon L, Meyer, Lauren K, Shannon, Kevin M, Teachey, David T   +5 more
core   +2 more sources

JAK Inhibitors — More Than Just Glucocorticoids

New England Journal of Medicine, 2021
Most persons who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are asymptomatic or have only mild-to-moderate symptoms, whereas others have progression to severe di...
Justin Stebbing, Volker M. Lauschke
openaire   +4 more sources

A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus

Journal of Pharmacological Sciences, 2021
Systemic lupus erythematosus is a chronic inflammatory disease, in which treatment is still limited due to suboptimal efficacy and toxicities associated with the available therapies.
Maria Dulak-Lis, Anna Bujak, Kamila Gala, Martyna Banach, Urszula Kędzierska, Joanna Miszkiel, Joanna Hucz-Kalitowska, Michał Mroczkiewicz, Bartosz Stypik, Krzysztof Szymczak, Paweł Gunerka, Krzysztof Dubiel, Beata M. Zygmunt, Maciej Wieczorek, Jerzy S. Pieczykolan   +14 more
doaj   +1 more source